BioTime, Inc. (BTX) Buy Target $1.22 – Sell Target $1.41

Buy Target $1.22Sell Target $1.41
Trailing Stop 20%

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration